

2
3. (Twice amended) The protein of claim 1 comprising an amino acid sequence [having] wherein said protein comprises SEQ ID No: 4 and has sequence homology equal to or greater than 80% to SEQ ID Nos: 2[,] or 3 [or 4].

28. (Twice amended) A method for treating an angiogenesis-related disease or disorder comprising administering an effective amount of the proteins or peptides of any one of claims 1 or [and] 3-8 to a patient in need thereof.

3
29. (Twice amended) A method for manufacturing a composition for the treatment of an angiogenesis-related disease comprising mixing the peptides according to any one of claims 1 or [and] 3-8 with a suitable pharmaceutical carrier.

Ab G1
30. (Twice amended) A composition comprising a protein or peptide according to any one of claims 1 [and] or 3-8 together with a pharmaceutically acceptable carrier wherein said protein or said peptide does not cleave plasminogen kringle domains.

Status of the Claims

By the above amendments, Claims 1, 3-8 and 28-33 are pending. Support for the amendments are as follows: